Magtein Approved as Novel Food in UK, Two Years Post-EU Clearance
Magtein, a patented form of Magnesium L-Threonate, has secured novel food approval in the UK, creating new formulation and market entry opportunities for cognitive health supplements, two years after its EU authorisation.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 20 March 2026
Magtein (Magnesium L-Threonate), a proprietary ingredient developed by AIDP and its partners, has received novel food approval in the United Kingdom. This milestone follows its European Union authorisation two years prior, effectively harmonising its regulatory status across both markets. The approval unlocks significant opportunities for UK supplement manufacturers and brand owners operating within the cognitive health category.
Magnesium L-Threonate is specifically engineered to enhance magnesium bioavailability in the brain, a key differentiating factor from other magnesium forms. Its patented status positions it as a premium ingredient, allowing for specific claims related to memory, learning, and overall cognitive function, based on existing scientific literature and regulatory precedents in other markets.
This development is particularly relevant as consumer interest in brain health continues to surge, driven by an aging demographic and increased awareness of cognitive decline. The market for cognitive health supplements in the UK is highly competitive, and novel, scientifically substantiated ingredients like Magtein offer a distinct advantage for product differentiation and premium pricing strategies.
Manufacturers should anticipate potential demand shifts towards products incorporating Magtein. This translates into strategic planning for procurement, supply chain adjustments, and reformulation. Initial product launches are expected to target the high-end segment of the market, focusing on consumers willing to invest in advanced cognitive support solutions.
What this means for United Kingdom
UK brand owners can now integrate Magtein into novel brain health formulations, directly addressing a growing consumer segment seeking advanced cognitive support. This provides a competitive edge against brands limited to conventional magnesium forms or unapproved novel ingredients. Manufacturers must navigate new supply chain logistics and potentially higher ingredient costs, but these are offset by the ingredient's premium positioning and established efficacy, supporting higher retail price points and improved margins. Regulatory teams should leverage Magtein's existing scientific dossier to expedite product claims authorisations, ensuring compliant marketing. The market dynamics will likely see early adopters gain significant share in the rapidly expanding cognitive health category over the next 18-24 months.
The regulatory pathway for Magtein in the UK mirrors the EU approval process, streamlining compliance for companies operating across both jurisdictions. This consistency reduces red-tape for product launches, offering a clear route to market for a category often scrutinised for substantiation of claims. The approval is expected to catalyse innovation in the British nutraceutical sector, fostering a new wave of products focused on targeted cognitive benefits.
Many leading brands in this category are manufactured in partnership with Supplement Factory.